A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.

MLA

Seiden, Michael V., et al. “A Phase II Study of Irofulven in Women with Recurrent and Heavily Pretreated Ovarian Cancer.” Gynecologic Oncology, vol. 101, no. 1, Apr. 2006, pp. 55–61. EBSCOhost, https://doi.org/10.1016/j.ygyno.2005.09.036.

APA

Seiden, M. V., Gordon, A. N., Bodurka, D. C., Matulonis, U. A., Penson, R. T., Reed, E., Alberts, D. S., Weems, G., Cullen, M., & McGuire, W. P., 3rd. (2006). A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecologic Oncology, 101(1), 55–61. https://doi.org/10.1016/j.ygyno.2005.09.036

Chicago

Seiden, Michael V, Alan N Gordon, Diane C Bodurka, Ursula A Matulonis, Richard T Penson, Eddie Reed, Dave S Alberts, Garry Weems, Michael Cullen, and William P McGuire 3rd. 2006. “A Phase II Study of Irofulven in Women with Recurrent and Heavily Pretreated Ovarian Cancer.” Gynecologic Oncology 101 (1): 55–61. doi:10.1016/j.ygyno.2005.09.036.